Currently, optimal treatment for patients with COVID‐19 is still uncertain and both interventions, blocking of IFN signaling by JAK/STAT inhibition [35, 36] or the use of different types of IFN as substitutions, have been suggested as a treatment for COVID‐19 and showed efficacy in small clinical trials [37, 38]. The gene discussed is SOAT1; the disease is COVID-19.